Intellia Thera CS NTLA

$9.77 -0.01 (-0.10%)

Valuation

Market cap
1,372,711,000
Revenue TTM
$67,670,000
Net income TTM
$-412,690,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-609.86%
Debt to equity
0.00

Trading

Volume
7,231,700
Avg volume
5,164,888
Day's range
$9.66 – $10.49
Shares out
140,359,000
Stochastic %K
4%
Beta
1.83
Analysts
Hold
Price target
$21.94

Price

Company profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. T...

Show more

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
(857) 285-6200
Website
https://www.intelliatx.com
Address
400 Technology Square, Suite 100, Cambridge, United States

Latest news

Stocktwits

Michaelthoaicaonguyen Nov 18, 9:25 PM
$IXHL $NTLA $ABAT $APLD $SLNH So I guess we just gonna stall at 7K, 27k, and at 62k for the rest of the year. Year-end sale off for tax purposes.
0 replies
Steelman111 Nov 18, 9:20 PM
$NTLA tomorrow we fight again.
0 replies
JoinTheDiscussionGroup26 Nov 18, 8:40 PM
🧬 Biotechnology: Clinical Progress Can Change Valuations Quickly Biotechnology stocks often respond strongly to clinical trial results and regulatory developments. $CRSP is developing gene-editing technologies, while $NTLA focuses on genome-editing treatments. $BEAM is advancing precision genetic medicine. Clinical milestones, cash reserves, regulatory decisions, and commercialization timelines are essential to monitor.
0 replies
Pharmer_ Nov 18, 6:54 PM
$NTLA WT hell is wrong with you. Nasdaq is up, Beam is up, Crispr is up, Lonvo-z data are good, Nex-z data are good, approval around the corner, cash position well into 2028.. You don't have to trade near a YTD low... Nothing is holding you back!
2 replies
woodhous Nov 18, 6:20 PM 1 replies
Dolphinsarecute Nov 18, 5:35 PM
$NTLA You're all talking about shorts, like a freaking mantra or something. Buy when it goes down, sell when it goes up. Bio, stockmarket - hello? Volitality? You don't "trade" biostocks unless you're extremely good at it. And if you were, you wouldn't sit here on a personal account, you'd be quiet or learning. Fubo is the biggest shitposter here. He never has anything to back up his claims and he loves lying, yet he has brought more to the table than 99% of the "bulls" here.
0 replies
Shirzo Nov 18, 5:35 PM 0 replies
SignoreRossi Nov 18, 4:20 PM
$NTLA going up and shorted down in a non ending loop - Q1 27 will be the show stopper time for shorties.
1 replies